Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Content from other channels on our network

Liquid metal to 'harvest' clean hydrogen from water

Epson makes progress with sustainability plans and initiatives in Australia and New Zealand

Sustainable wastewater treatment achieved for urban areas

'Brownfielding' increases to meet metal demand

NSW to exceed energy storage targets

Why physical device security is becoming a patient privacy issue in health care

Food waste in Australian hospitals and aged care homes — can AI help?

Legislation introduced to improve private health choice and transparency

WA healthcare professionals gain workplace-specific courses

InterSystems Honoured with Four 2026 Best in KLAS Awards

Dairy drinks maker installed aseptic PET packaging line at greenfield facility

Robots that see around corners

Health Star Ratings set to become regulated in Australia and NZ

Fast detection of food contamination using enhanced AI tool

Abattoir safety program in WA raises more awareness